New Psychoactive Substance-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data
Report Summary
New Psychoactive Substance-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on New Psychoactive Substance industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of New Psychoactive Substance 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of New Psychoactive Substance worldwide and market share by regions, with company and product introduction, position in the New Psychoactive Substance market
Market status and development trend of New Psychoactive Substance by types and applications
Cost and profit status of New Psychoactive Substance, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium New Psychoactive Substance market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the New Psychoactive Substance industry.
The report segments the global New Psychoactive Substance market as:
Global New Psychoactive Substance Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global New Psychoactive Substance Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Stimulants
Cannabinoids
Hallucinogens
Depressants
Global New Psychoactive Substance Market: Application Segment Analysis (Consumption Volume and Market Share 206-2026; Downstream Customers and Market Analysis)
Cancer
Neuropathic Disorders
Spasticity
Others
Global New Psychoactive Substance Market: Manufacturers Segment Analysis (Company and Product introduction, New Psychoactive Substance Sales Volume, Revenue, Price and Gross Margin):
Zynerba Pharmaceuticals
GW Pharmaceuticals
Teewinot Life Sciences
AusCann
Cannabics Pharmaceuticals
Tilray
Cyrelian
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
New Psychoactive Substance-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on New Psychoactive Substance industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of New Psychoactive Substance 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of New Psychoactive Substance worldwide and market share by regions, with company and product introduction, position in the New Psychoactive Substance market
Market status and development trend of New Psychoactive Substance by types and applications
Cost and profit status of New Psychoactive Substance, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium New Psychoactive Substance market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the New Psychoactive Substance industry.
The report segments the global New Psychoactive Substance market as:
Global New Psychoactive Substance Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global New Psychoactive Substance Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Stimulants
Cannabinoids
Hallucinogens
Depressants
Global New Psychoactive Substance Market: Application Segment Analysis (Consumption Volume and Market Share 206-2026; Downstream Customers and Market Analysis)
Cancer
Neuropathic Disorders
Spasticity
Others
Global New Psychoactive Substance Market: Manufacturers Segment Analysis (Company and Product introduction, New Psychoactive Substance Sales Volume, Revenue, Price and Gross Margin):
Zynerba Pharmaceuticals
GW Pharmaceuticals
Teewinot Life Sciences
AusCann
Cannabics Pharmaceuticals
Tilray
Cyrelian
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NEW PSYCHOACTIVE SUBSTANCE
1.1 Definition of New Psychoactive Substance in This Report
1.2 Commercial Types of New Psychoactive Substance
1.2.1 Stimulants
1.2.2 Cannabinoids
1.2.3 Hallucinogens
1.2.4 Depressants
1.3 Downstream Application of New Psychoactive Substance
1.3.1 Cancer
1.3.2 Neuropathic Disorders
1.3.3 Spasticity
1.3.4 Others
1.4 Development History of New Psychoactive Substance
1.5 Market Status and Trend of New Psychoactive Substance 2016-2026
1.5.1 Global New Psychoactive Substance Market Status and Trend 2016-2026
1.5.2 Regional New Psychoactive Substance Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of New Psychoactive Substance 2016-2021
2.2 Sales Market of New Psychoactive Substance by Regions
2.2.1 Sales Volume of New Psychoactive Substance by Regions
2.2.2 Sales Value of New Psychoactive Substance by Regions
2.3 Production Market of New Psychoactive Substance by Regions
2.4 Global Market Forecast of New Psychoactive Substance 2022-2026
2.4.1 Global Market Forecast of New Psychoactive Substance 2022-2026
2.4.2 Market Forecast of New Psychoactive Substance by Regions 2022-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of New Psychoactive Substance by Types
3.2 Sales Value of New Psychoactive Substance by Types
3.3 Market Forecast of New Psychoactive Substance by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of New Psychoactive Substance by Downstream Industry
4.2 Global Market Forecast of New Psychoactive Substance by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America New Psychoactive Substance Market Status by Countries
5.1.1 North America New Psychoactive Substance Sales by Countries (2016-2021)
5.1.2 North America New Psychoactive Substance Revenue by Countries (2016-2021)
5.1.3 United States New Psychoactive Substance Market Status (2016-2021)
5.1.4 Canada New Psychoactive Substance Market Status (2016-2021)
5.1.5 Mexico New Psychoactive Substance Market Status (2016-2021)
5.2 North America New Psychoactive Substance Market Status by Manufacturers
5.3 North America New Psychoactive Substance Market Status by Type (2016-2021)
5.3.1 North America New Psychoactive Substance Sales by Type (2016-2021)
5.3.2 North America New Psychoactive Substance Revenue by Type (2016-2021)
5.4 North America New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe New Psychoactive Substance Market Status by Countries
6.1.1 Europe New Psychoactive Substance Sales by Countries (2016-2021)
6.1.2 Europe New Psychoactive Substance Revenue by Countries (2016-2021)
6.1.3 Germany New Psychoactive Substance Market Status (2016-2021)
6.1.4 UK New Psychoactive Substance Market Status (2016-2021)
6.1.5 France New Psychoactive Substance Market Status (2016-2021)
6.1.6 Italy New Psychoactive Substance Market Status (2016-2021)
6.1.7 Russia New Psychoactive Substance Market Status (2016-2021)
6.1.8 Spain New Psychoactive Substance Market Status (2016-2021)
6.1.9 Benelux New Psychoactive Substance Market Status (2016-2021)
6.2 Europe New Psychoactive Substance Market Status by Manufacturers
6.3 Europe New Psychoactive Substance Market Status by Type (2016-2021)
6.3.1 Europe New Psychoactive Substance Sales by Type (2016-2021)
6.3.2 Europe New Psychoactive Substance Revenue by Type (2016-2021)
6.4 Europe New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific New Psychoactive Substance Market Status by Countries
7.1.1 Asia Pacific New Psychoactive Substance Sales by Countries (2016-2021)
7.1.2 Asia Pacific New Psychoactive Substance Revenue by Countries (2016-2021)
7.1.3 China New Psychoactive Substance Market Status (2016-2021)
7.1.4 Japan New Psychoactive Substance Market Status (2016-2021)
7.1.5 India New Psychoactive Substance Market Status (2016-2021)
7.1.6 Southeast Asia New Psychoactive Substance Market Status (2016-2021)
7.1.7 Australia New Psychoactive Substance Market Status (2016-2021)
7.2 Asia Pacific New Psychoactive Substance Market Status by Manufacturers
7.3 Asia Pacific New Psychoactive Substance Market Status by Type (2016-2021)
7.3.1 Asia Pacific New Psychoactive Substance Sales by Type (2016-2021)
7.3.2 Asia Pacific New Psychoactive Substance Revenue by Type (2016-2021)
7.4 Asia Pacific New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America New Psychoactive Substance Market Status by Countries
8.1.1 Latin America New Psychoactive Substance Sales by Countries (2016-2021)
8.1.2 Latin America New Psychoactive Substance Revenue by Countries (2016-2021)
8.1.3 Brazil New Psychoactive Substance Market Status (2016-2021)
8.1.4 Argentina New Psychoactive Substance Market Status (2016-2021)
8.1.5 Colombia New Psychoactive Substance Market Status (2016-2021)
8.2 Latin America New Psychoactive Substance Market Status by Manufacturers
8.3 Latin America New Psychoactive Substance Market Status by Type (2016-2021)
8.3.1 Latin America New Psychoactive Substance Sales by Type (2016-2021)
8.3.2 Latin America New Psychoactive Substance Revenue by Type (2016-2021)
8.4 Latin America New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa New Psychoactive Substance Market Status by Countries
9.1.1 Middle East and Africa New Psychoactive Substance Sales by Countries (2016-2021)
9.1.2 Middle East and Africa New Psychoactive Substance Revenue by Countries (2016-2021)
9.1.3 Middle East New Psychoactive Substance Market Status (2016-2021)
9.1.4 Africa New Psychoactive Substance Market Status (2016-2021)
9.2 Middle East and Africa New Psychoactive Substance Market Status by Manufacturers
9.3 Middle East and Africa New Psychoactive Substance Market Status by Type (2016-2021)
9.3.1 Middle East and Africa New Psychoactive Substance Sales by Type (2016-2021)
9.3.2 Middle East and Africa New Psychoactive Substance Revenue by Type (2016-2021)
9.4 Middle East and Africa New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
10.1 Global Economy Situation and Trend Overview
10.2 New Psychoactive Substance Downstream Industry Situation and Trend Overview
CHAPTER 11 NEW PSYCHOACTIVE SUBSTANCE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of New Psychoactive Substance by Major Manufacturers
11.2 Production Value of New Psychoactive Substance by Major Manufacturers
11.3 Basic Information of New Psychoactive Substance by Major Manufacturers
11.3.1 Headquarters Location and Established Time of New Psychoactive Substance Major Manufacturer
11.3.2 Employees and Revenue Level of New Psychoactive Substance Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 NEW PSYCHOACTIVE SUBSTANCE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Zynerba Pharmaceuticals
12.1.1 Company profile
12.1.2 Representative New Psychoactive Substance Product
12.1.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Zynerba Pharmaceuticals
12.2 GW Pharmaceuticals
12.2.1 Company profile
12.2.2 Representative New Psychoactive Substance Product
12.2.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of GW Pharmaceuticals
12.3 Teewinot Life Sciences
12.3.1 Company profile
12.3.2 Representative New Psychoactive Substance Product
12.3.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Teewinot Life Sciences
12.4 AusCann
12.4.1 Company profile
12.4.2 Representative New Psychoactive Substance Product
12.4.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of AusCann
12.5 Cannabics Pharmaceuticals
12.5.1 Company profile
12.5.2 Representative New Psychoactive Substance Product
12.5.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cannabics Pharmaceuticals
12.6 Tilray
12.6.1 Company profile
12.6.2 Representative New Psychoactive Substance Product
12.6.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Tilray
12.7 Cyrelian
12.7.1 Company profile
12.7.2 Representative New Psychoactive Substance Product
12.7.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cyrelian
12.8 Anandia Laboratories
12.8.1 Company profile
12.8.2 Representative New Psychoactive Substance Product
12.8.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Anandia Laboratories
12.9 InMed Pharmaceuticals
12.9.1 Company profile
12.9.2 Representative New Psychoactive Substance Product
12.9.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of InMed Pharmaceuticals
12.10 Renew Biopharma
12.10.1 Company profile
12.10.2 Representative New Psychoactive Substance Product
12.10.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Renew Biopharma
12.11 Cronos Group
12.11.1 Company profile
12.11.2 Representative New Psychoactive Substance Product
12.11.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cronos Group
12.12 ICC International Cannabis
12.12.1 Company profile
12.12.2 Representative New Psychoactive Substance Product
12.12.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of ICC International Cannabis
12.13 Biotii Technologies
12.13.1 Company profile
12.13.2 Representative New Psychoactive Substance Product
12.13.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Biotii Technologies
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
13.1 Industry Chain of New Psychoactive Substance
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
14.1 Cost Structure Analysis of New Psychoactive Substance
14.2 Raw Materials Cost Analysis of New Psychoactive Substance
14.3 Labor Cost Analysis of New Psychoactive Substance
14.4 Manufacturing Expenses Analysis of New Psychoactive Substance
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of New Psychoactive Substance in This Report
1.2 Commercial Types of New Psychoactive Substance
1.2.1 Stimulants
1.2.2 Cannabinoids
1.2.3 Hallucinogens
1.2.4 Depressants
1.3 Downstream Application of New Psychoactive Substance
1.3.1 Cancer
1.3.2 Neuropathic Disorders
1.3.3 Spasticity
1.3.4 Others
1.4 Development History of New Psychoactive Substance
1.5 Market Status and Trend of New Psychoactive Substance 2016-2026
1.5.1 Global New Psychoactive Substance Market Status and Trend 2016-2026
1.5.2 Regional New Psychoactive Substance Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of New Psychoactive Substance 2016-2021
2.2 Sales Market of New Psychoactive Substance by Regions
2.2.1 Sales Volume of New Psychoactive Substance by Regions
2.2.2 Sales Value of New Psychoactive Substance by Regions
2.3 Production Market of New Psychoactive Substance by Regions
2.4 Global Market Forecast of New Psychoactive Substance 2022-2026
2.4.1 Global Market Forecast of New Psychoactive Substance 2022-2026
2.4.2 Market Forecast of New Psychoactive Substance by Regions 2022-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of New Psychoactive Substance by Types
3.2 Sales Value of New Psychoactive Substance by Types
3.3 Market Forecast of New Psychoactive Substance by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of New Psychoactive Substance by Downstream Industry
4.2 Global Market Forecast of New Psychoactive Substance by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America New Psychoactive Substance Market Status by Countries
5.1.1 North America New Psychoactive Substance Sales by Countries (2016-2021)
5.1.2 North America New Psychoactive Substance Revenue by Countries (2016-2021)
5.1.3 United States New Psychoactive Substance Market Status (2016-2021)
5.1.4 Canada New Psychoactive Substance Market Status (2016-2021)
5.1.5 Mexico New Psychoactive Substance Market Status (2016-2021)
5.2 North America New Psychoactive Substance Market Status by Manufacturers
5.3 North America New Psychoactive Substance Market Status by Type (2016-2021)
5.3.1 North America New Psychoactive Substance Sales by Type (2016-2021)
5.3.2 North America New Psychoactive Substance Revenue by Type (2016-2021)
5.4 North America New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe New Psychoactive Substance Market Status by Countries
6.1.1 Europe New Psychoactive Substance Sales by Countries (2016-2021)
6.1.2 Europe New Psychoactive Substance Revenue by Countries (2016-2021)
6.1.3 Germany New Psychoactive Substance Market Status (2016-2021)
6.1.4 UK New Psychoactive Substance Market Status (2016-2021)
6.1.5 France New Psychoactive Substance Market Status (2016-2021)
6.1.6 Italy New Psychoactive Substance Market Status (2016-2021)
6.1.7 Russia New Psychoactive Substance Market Status (2016-2021)
6.1.8 Spain New Psychoactive Substance Market Status (2016-2021)
6.1.9 Benelux New Psychoactive Substance Market Status (2016-2021)
6.2 Europe New Psychoactive Substance Market Status by Manufacturers
6.3 Europe New Psychoactive Substance Market Status by Type (2016-2021)
6.3.1 Europe New Psychoactive Substance Sales by Type (2016-2021)
6.3.2 Europe New Psychoactive Substance Revenue by Type (2016-2021)
6.4 Europe New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific New Psychoactive Substance Market Status by Countries
7.1.1 Asia Pacific New Psychoactive Substance Sales by Countries (2016-2021)
7.1.2 Asia Pacific New Psychoactive Substance Revenue by Countries (2016-2021)
7.1.3 China New Psychoactive Substance Market Status (2016-2021)
7.1.4 Japan New Psychoactive Substance Market Status (2016-2021)
7.1.5 India New Psychoactive Substance Market Status (2016-2021)
7.1.6 Southeast Asia New Psychoactive Substance Market Status (2016-2021)
7.1.7 Australia New Psychoactive Substance Market Status (2016-2021)
7.2 Asia Pacific New Psychoactive Substance Market Status by Manufacturers
7.3 Asia Pacific New Psychoactive Substance Market Status by Type (2016-2021)
7.3.1 Asia Pacific New Psychoactive Substance Sales by Type (2016-2021)
7.3.2 Asia Pacific New Psychoactive Substance Revenue by Type (2016-2021)
7.4 Asia Pacific New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America New Psychoactive Substance Market Status by Countries
8.1.1 Latin America New Psychoactive Substance Sales by Countries (2016-2021)
8.1.2 Latin America New Psychoactive Substance Revenue by Countries (2016-2021)
8.1.3 Brazil New Psychoactive Substance Market Status (2016-2021)
8.1.4 Argentina New Psychoactive Substance Market Status (2016-2021)
8.1.5 Colombia New Psychoactive Substance Market Status (2016-2021)
8.2 Latin America New Psychoactive Substance Market Status by Manufacturers
8.3 Latin America New Psychoactive Substance Market Status by Type (2016-2021)
8.3.1 Latin America New Psychoactive Substance Sales by Type (2016-2021)
8.3.2 Latin America New Psychoactive Substance Revenue by Type (2016-2021)
8.4 Latin America New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa New Psychoactive Substance Market Status by Countries
9.1.1 Middle East and Africa New Psychoactive Substance Sales by Countries (2016-2021)
9.1.2 Middle East and Africa New Psychoactive Substance Revenue by Countries (2016-2021)
9.1.3 Middle East New Psychoactive Substance Market Status (2016-2021)
9.1.4 Africa New Psychoactive Substance Market Status (2016-2021)
9.2 Middle East and Africa New Psychoactive Substance Market Status by Manufacturers
9.3 Middle East and Africa New Psychoactive Substance Market Status by Type (2016-2021)
9.3.1 Middle East and Africa New Psychoactive Substance Sales by Type (2016-2021)
9.3.2 Middle East and Africa New Psychoactive Substance Revenue by Type (2016-2021)
9.4 Middle East and Africa New Psychoactive Substance Market Status by Downstream Industry (2016-2021)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
10.1 Global Economy Situation and Trend Overview
10.2 New Psychoactive Substance Downstream Industry Situation and Trend Overview
CHAPTER 11 NEW PSYCHOACTIVE SUBSTANCE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of New Psychoactive Substance by Major Manufacturers
11.2 Production Value of New Psychoactive Substance by Major Manufacturers
11.3 Basic Information of New Psychoactive Substance by Major Manufacturers
11.3.1 Headquarters Location and Established Time of New Psychoactive Substance Major Manufacturer
11.3.2 Employees and Revenue Level of New Psychoactive Substance Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 NEW PSYCHOACTIVE SUBSTANCE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Zynerba Pharmaceuticals
12.1.1 Company profile
12.1.2 Representative New Psychoactive Substance Product
12.1.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Zynerba Pharmaceuticals
12.2 GW Pharmaceuticals
12.2.1 Company profile
12.2.2 Representative New Psychoactive Substance Product
12.2.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of GW Pharmaceuticals
12.3 Teewinot Life Sciences
12.3.1 Company profile
12.3.2 Representative New Psychoactive Substance Product
12.3.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Teewinot Life Sciences
12.4 AusCann
12.4.1 Company profile
12.4.2 Representative New Psychoactive Substance Product
12.4.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of AusCann
12.5 Cannabics Pharmaceuticals
12.5.1 Company profile
12.5.2 Representative New Psychoactive Substance Product
12.5.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cannabics Pharmaceuticals
12.6 Tilray
12.6.1 Company profile
12.6.2 Representative New Psychoactive Substance Product
12.6.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Tilray
12.7 Cyrelian
12.7.1 Company profile
12.7.2 Representative New Psychoactive Substance Product
12.7.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cyrelian
12.8 Anandia Laboratories
12.8.1 Company profile
12.8.2 Representative New Psychoactive Substance Product
12.8.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Anandia Laboratories
12.9 InMed Pharmaceuticals
12.9.1 Company profile
12.9.2 Representative New Psychoactive Substance Product
12.9.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of InMed Pharmaceuticals
12.10 Renew Biopharma
12.10.1 Company profile
12.10.2 Representative New Psychoactive Substance Product
12.10.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Renew Biopharma
12.11 Cronos Group
12.11.1 Company profile
12.11.2 Representative New Psychoactive Substance Product
12.11.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cronos Group
12.12 ICC International Cannabis
12.12.1 Company profile
12.12.2 Representative New Psychoactive Substance Product
12.12.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of ICC International Cannabis
12.13 Biotii Technologies
12.13.1 Company profile
12.13.2 Representative New Psychoactive Substance Product
12.13.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Biotii Technologies
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
13.1 Industry Chain of New Psychoactive Substance
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
14.1 Cost Structure Analysis of New Psychoactive Substance
14.2 Raw Materials Cost Analysis of New Psychoactive Substance
14.3 Labor Cost Analysis of New Psychoactive Substance
14.4 Manufacturing Expenses Analysis of New Psychoactive Substance
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
